The Heart in Hypertension

Session A: Cardiac Performance in Experimental Hypertension.- I: Pathogenesis of Experimental Hypertension: Ventricular Function and Myocardial Contractility.- Experimental Hypertension and Its Significance for Clinical Hypertension.- Left Ventricular Hypertrophy in Chronic Pressure Load Due to Spontaneous Essential Hypertension Left Ventricular Function, Left Ventricular Geometry, and Wall Stress.- Left Ventricular Hypertrophy in Chronic Pressure Load Due to Spontaneous Essential Hypertension Contractility of the Isolated Left Ventricular Myocardium, and Left Ventricular Stiffness.- Systemic Hemodynamics and Cardiac Function in the Spontaneously Hypertensive Rat: Similarities with Essential Hypertension.- II: Myocardial, Adrenergic and Noncontractile Responses.- Reversal of Cardiac Hypertrophy by Antihypertensive Therapy.- Left Ventricular Dynamics and Myocardial Function in Goldblatt Hypertension of the Rat Biochemical, Morphological and Electrophysiological Correlates.- Catecholamines in Experimental and Essential Hypertension.- Session B: Cardiac Mechanochemistry and Morphology in Various Forms of Hypertensive Heart Disease.- I: Contractile Proteins and Contraction Energetics.- Cardiac Myosin in Heart Overloading.- Properties of Myocardial Myosin in Left Ventricular Hypertrophy Due to Spontaneous Essential Hypertension in Rats.- Cross Bridge Mechanics in the Heart Muscle of Spontaneously Hypertensive Rats.- The Utilization of Energy by the Myocardium Hypertrophied Secondary to Pressure Overload.- Coronary Haemodynamics and Myocardial Adenosine Release Under the Influence of Digitalis Glycosides (Digoxin).- II: Microscopic Pathology of the Myocardium and Coronary Arteries.- Microscopic Pathology of the Heart Muscle and of Coronary Arteries in Arterial Hypertension.-Microscopic Pathology of Intramural Coronary Arteries and Arterioles of the Left Ventricle in Arterial Hypertension.- Reduced Coronary Reserve, and Ultrastructural Changes of the Myocardium in Patients with Angina Pectoris, Arterial Hypertension, and Normal Coronary Arteries.- Session C: Cardiac Function and Metabolism in Clinical Hypertension.- I: Pathogenetic Implications, Ventricular Wall Dynamics and Coronary Circulation.- Left Ventricular Hypertrophy in Hypertension: Prognostic and Pathogenetic Implications (The Framingham Study).- Structural Adaptation of the Heart in Hypertension and the Physical Consequences.- Performance, Wall Dynamics and Coronary Function of the Left Ventricle in Hypertensive Heart Disease.- II: Afterload Changes and Ventricular Function.- The Pressure Overloaded Heart: Physiological and Clinical Correlates.- Effect of Systemic Vasoconstriction on Left Ventricular Function: Implications Regarding Hypertension and Heart Failure.- Ventricular Function and Coronary Hemodynamics Under the Influence of Vasodilating Agents.- Session D: Central Haemodynamics, Regional Wall Mechanics, and Ventricular Relaxation in Clinical Hypertension.- I: Central Haemodynamics at Rest and During Exercise.- Central Haemodynamics in Hypertension at Rest and During Exercise.- Arterial Hypertension: Left Ventricular Function at Rest and During Exercise.- Assessment of Left Ventricular Muscle Mass with 201 Thallium Myocardial Imaging.- II: Noninvasive Assessment of Ventricular Contraction and Relaxation.- Detection of Abnormal Left Ventricular Performance During Early Systole in Patients with Chronic Pressure Overload Due to Systemic Arterial Hypertension.- Quantitative Echocardiographic Analysis of Pharmacological Stress Testing in Essential Hypertension.- Left Ventricular Relaxation and Filling Pattern in Different Forms of Left Ventricular Hypertrophy.- Session E: Therapy of Hypertensive Heart Disease.- I: Therapeutical Management of Hypertrophy and Heart Failure.- Impaired Cardiac Performance in Rats with Long-Term Spontaneous Hypertension.- Pathophysiologic Basis of Antihypertensive Therapy in Man.- Central Hemodynamics at Rest and During Exercise Following Intravenous Digoxin in Hypertension.- II: Use of Beta-Receptor Blocking Agents.- Beta-Adrenergic Receptor Blockade in the Treatment of Essential Hypertension.- Beta-Receptor Blockade in the Treatment of Renal Hypertension.- Left Ventricular and Coronary Response to Beta-Receptor Blockade in Essential Hypertension.